On the heels of a glob­al R&D re­or­ga­ni­za­tion, No­vo Nordisk out­lines 250 US job cuts

No­vo Nordisk is slash­ing 250 US jobs in an on­go­ing re­or­ga­ni­za­tion of the busi­ness.

Med­Watch re­port­ed that the phar­ma com­pa­ny is whack­ing 100 back of­fice jobs while elim­i­nat­ing an­oth­er 150 “ed­u­ca­tors” in­volved in its di­a­betes busi­ness.

The lat­est cut­backs fol­low close­ly on a plan to re­struc­ture its $1 bil­lion R&D or­ga­ni­za­tion. Just days ago the com­pa­ny out­lined a plan to ax 400 R&D jobs in Chi­na and Den­mark as they set up 4 new re­search groups in In­di­anapo­lis, the UK and their home base in Den­mark. The unit in In­di­anapo­lis, home town to ri­val Eli Lil­ly, will fo­cus on di­a­betes and obe­si­ty, a ma­jor theme at No­vo while the Ox­ford team con­cen­trates on car­dio-meta­bol­ic re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER